3,4-methylenedioxyamphetamine and Wolff-Parkinson-White Syndrome

3,4-methylenedioxyamphetamine has been researched along with Wolff-Parkinson-White Syndrome in 1 studies

3,4-Methylenedioxyamphetamine: An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally.

Wolff-Parkinson-White Syndrome: A form of ventricular pre-excitation characterized by a short PR interval and a long QRS interval with a delta wave. In this syndrome, atrial impulses are abnormally conducted to the HEART VENTRICLES via an ACCESSORY CONDUCTING PATHWAY that is located between the wall of the right or left atria and the ventricles, also known as a BUNDLE OF KENT. The inherited form can be caused by mutation of PRKAG2 gene encoding a gamma-2 regulatory subunit of AMP-activated protein kinase.

Research

Studies (1)

Authors

Other Studies

1 other study available for 3,4-methylenedioxyamphetamine and Wolff-Parkinson-White Syndrome